CDKN2A and cancer: Consistent with this, ABT-737, which inhibits Bcl2, Bcl-xl and Bcl-w, reduced the numbers of p16+ cancer cells (as we have previously shown18), whereas the Bcl2-specific inhibitor ABT-199 achieved better elimination of the stromal senescent cells (Supplementary Fig. 9b, c).